Area of research
Immunology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Phagocytosis and Immune Regulation, Monoclonal and Polyclonal Antibodies Research, Immune cells in cancer, and Immune Cell Function and Interaction.
MMD collaborates with ACSL4 and MBOAT7 to promote polyunsaturated phosphatidylinositol remodeling and susceptibility to ferroptosis
MMD scaffolds ACSL4 and MBOAT7 to promote polyunsaturated phospholipid synthesis and susceptibility to ferroptosis
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts
Salmonella Infection Enhances Erythropoietin Production by the Kidney and Liver, Which Correlates with Elevated Bacterial Burdens
Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
“Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis
Targeting CD137 enhances the efficacy of cetuximab
Successful Engraftment of Hematopoietic Stem Cells into Immunocompetent Recipients Using Only Anti-CD117 Antibody and CD47 Blockade As Conditioning
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors